Fulcrum Therapeutics Inc
NASDAQ:FULC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.16
12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
Income from Continuing Operations
Fulcrum Therapeutics Inc
Income from Continuing Operations Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Income from Continuing Operations
-$20.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$14.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$7.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-9%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$12.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$8.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
See Also
What is Fulcrum Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-20.2m
USD
Based on the financial report for Jun 30, 2024, Fulcrum Therapeutics Inc's Income from Continuing Operations amounts to -20.2m USD.
What is Fulcrum Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
21%
Over the last year, the Income from Continuing Operations growth was 79%. The average annual Income from Continuing Operations growth rates for Fulcrum Therapeutics Inc have been 35% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
